161

PATENT

Attorney Docket No.
DX0686Q

CN 028008

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Examiner: Jamroz, M
GORMAN & MATTSON	Art Unit: 1644
Serial No.: 09/671,658	COMPUTER READABLE SEQUENCE SUBMISSION
Filed: September 27, 2000	Palo Alto, California 94304
For: MAMMALIAN CELL SURFACE ANTIGENS; RELATED REAGENTS	November 9, 2001

5

BOX: Sequence
Assistant Commissioner for Patents
Washington, D.C. 20231

10 Sir:

COMPLIANCE WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

15   In reply to receipt of a "Notice to Comply" with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures dated November 5, 2001, for the above-identified application, in accordance with 37 CFR § 1.821 - 1.825, Applicants hereby submit: (1) a write-protected diskette containing a computer-readable submission for the "Sequence

20 Listing"; and (2) a "Sequence Listing" paper copy of the contents of the diskette.

REMARKS

        Enclosed is a write protected floppy diskette with the sequence listing

25 generated by the Patent Office's PATENTIN program. The Diskette should comply with the requirements of 37 CFR §1.824 and is IBM PC compatible with a PC-DOS/MS-DOS operating system. If the diskette has been damaged, please call Applicants and a replacement diskette will be provided. A hard paper copy printout of the diskette is attached thereto.

I hereby state the informational contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR 1.821(c) and (e), respectively, are believed to be the same. This submission

5   introduces no new matter, since enclosed sequences are the same as sequences which were submitted in priority documents.

Applicants have invested significant labor and care in preparing the present submission. The enclosed items are a bona fide effort to bring the present

10   application into full compliance with the rules for sequence submissions. Should this not be the case, Applicants respectfully request notification of specific deficiencies and an opportunity for remedy, as described in 37 CFR 1.135(c).

Applicants believe that no fees are required; however, if any fees are

15   required by the present Response, the Commissioner is authorized to charge any fees or credit any overpayment to DNAX Research Institute Deposit Account No. 04-1239.

Respectfully submitted,

20

Date: _November 9_, 2001   By: _Sheela Mohan-Peterson_
                                            Sheela Mohan-Peterson
                                            Attorney for Applicants
25   Reg. No. 41,201

enclosures and attachments:
         one write-protected diskette (CRM)
         paper copy of contents of diskette (4 pages)
30   Copy of "Notice to Comply" with sequence listing rules

DNAX Research Institute
35   901 California Avenue
     Palo Alto, California 94304-1104
     Main: (650) 496-6400
     Direct: (650) 496-1244
     Fax: (650) 496-1200

DETAILED ACTION

Sequence Compliance

1. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Applicant is reminded to amend the specification (including the Brief Description of Drawings) and claims as appropriate to reflect compliance with the Sequence Rules.

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Megan Jamroz, whose telephone number is (703) 308-8365. The examiner can normally be reached Monday to Friday from 8:00 to 4:30. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached at (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 305-3014.

Margaret (Megan) Jamroz, Ph.D.
Patent Examiner
Technology Center 1600
November 1, 2001

PHILLIP GAMBEL
PHILLIP GAMBEL, PH.D
PRIMARY EXAMINER
TECH CENTER 1600
11/2/01

	Application No.	Applicant(s)
Notice to Comply JAN 0 3 2002	09/671,658	GORMAN ET AL.
	Examiner	Art Unit
	Margaret E Jamroz	1644

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).

☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."

☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

☐ 7. Other:

Applicant Must Provide:
☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216
For CRF Submission Help, call (703) 308-4212
PatentIn Software Program Support
    Technical Assistance......................................703-287-0200
    To Purchase PatentIn Software........................703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

SEQUENCE LISTING

<110> Groman, Daniel M.
       Mattson, Jeanine D.

<120> MAMMALIAN CELL SURFACE ANTIGENS; RELATED REAGENTS

<130> DX0686Q

<140> US 09/671,658
<141> 2000-09-27

<150> US 08/989,362
<151> 1997-12-12

<150> US 60/032,846
<151> 1996-12-13

<160> 2

<170> PatentIn version 3.1

<210> 1
<211> 2191
<212> DNA
<213> Mus musculus

<220>
<221> CDS
<222> (125)..(1072)
<223>

<400> 1
gccaggacct ctgtgaaccg gtcgggcggg gggccgcctg ccgggagtc tgctcggcgg   60

tgggtggccg aggaagggag agaacgatcg cggagcaggg cgcccgaact ccgggcgccg   120

cgcc atg cgc cgg gcc agc cga gac tac ggc aag tac ctg cgc agc tcg   169
     Met Arg Arg Ala Ser Arg Asp Tyr Gly Lys Tyr Leu Arg Ser Ser
     1   5   10   15

gag gag atg ggc agc ggc ccc ggc gtc cca cac gag ggt ccg ctg cac   217
Glu Glu Met Gly Ser Gly Pro Gly Val Pro His Glu Gly Pro Leu His
                20   25   30

ccc gcg cct tct gca ccg gct ccg gcg ccg cca ccc gcc gcc tcc cgc   265
Pro Ala Pro Ser Ala Pro Ala Pro Ala Pro Pro Pro Ala Ala Ser Arg
            35   40   45

tcc atg ttc ctg gcc ctc ctg ggg ctg gga ctg ggc cag gtg gtc tgc   313
Ser Met Phe Leu Ala Leu Leu Gly Leu Gly Leu Gly Gln Val Val Cys
        50   55   60

agc atc gct ctg ttc ctg tac ttt cga gcg cag atg gat cct aac aga   361
Ser Ile Ala Leu Phe Leu Tyr Phe Arg Ala Gln Met Asp Pro Asn Arg
    65   70   75

ata tca gaa gac agc act cac tgc ttt tat aga atc ctg aga ctc cat   409
Ile Ser Glu Asp Ser Thr His Cys Phe Tyr Arg Ile Leu Arg Leu His
80   85   90   95

```
gaa aac gca ggt ttg cag gac tcg act ctg gag agt gaa gac aca cta        457
Glu Asn Ala Gly Leu Gln Asp Ser Thr Leu Glu Ser Glu Asp Thr Leu
            100                 105                 110

cct gac tcc tgc agg agg atg aaa caa gcc ttt cag ggg gcc gtg cag        505
Pro Asp Ser Cys Arg Arg Met Lys Gln Ala Phe Gln Gly Ala Val Gln
            115                 120                 125

aag gaa ctg caa cac att gtg ggg cca cag cgc ttc tca gga gct cca        553
Lys Glu Leu Gln His Ile Val Gly Pro Gln Arg Phe Ser Gly Ala Pro
            130                 135                 140

gct atg atg gaa ggc tca tgg ttg gat gtg gcc cag cga ggc aag cct        601
Ala Met Met Glu Gly Ser Trp Leu Asp Val Ala Gln Arg Gly Lys Pro
            145                 150                 155

gag gcc cag cca ttt gca cac ctc acc atc aat gct gcc agc atc cca        649
Glu Ala Gln Pro Phe Ala His Leu Thr Ile Asn Ala Ala Ser Ile Pro
160                 165                 170                 175

tcg ggt tcc cat aaa gtc act ctg tcc tct tgg tac cac gat cga ggc        697
Ser Gly Ser His Lys Val Thr Leu Ser Ser Trp Tyr His Asp Arg Gly
                180                 185                 190

tgg gcc aag atc tct aac atg acg tta agc aac gga aaa cta agg gtt        745
Trp Ala Lys Ile Ser Asn Met Thr Leu Ser Asn Gly Lys Leu Arg Val
                195                 200                 205

aac caa gat ggc ttc tat tac ctg tac gcc aac att tgc ttt cgg cat        793
Asn Gln Asp Gly Phe Tyr Tyr Leu Tyr Ala Asn Ile Cys Phe Arg His
            210                 215                 220

cat gaa aca tcg gga agc gta cct aca gac tat ctt cag ctg atg gtg        841
His Glu Thr Ser Gly Ser Val Pro Thr Asp Tyr Leu Gln Leu Met Val
            225                 230                 235

tat gtc gtt aaa acc agc atc aaa atc cca agt tct cat aac ctg atg        889
Tyr Val Val Lys Thr Ser Ile Lys Ile Pro Ser Ser His Asn Leu Met
240                 245                 250                 255

aaa gga ggg agc acg aaa aac tgg tcg ggc aat tct gaa ttc cac ttt        937
Lys Gly Gly Ser Thr Lys Asn Trp Ser Gly Asn Ser Glu Phe His Phe
                260                 265                 270

tat tcc ata aat gtt ggg gga ttt ttc aag ctc cga gct ggt gaa gaa        985
Tyr Ser Ile Asn Val Gly Gly Phe Phe Lys Leu Arg Ala Gly Glu Glu
                275                 280                 285

att agc att cag gtg tcc aac cct tcc ctg ctg gat ccg gat caa gat       1033
Ile Ser Ile Gln Val Ser Asn Pro Ser Leu Leu Asp Pro Asp Gln Asp
            290                 295                 300

gcg acg tac ttt ggg gct ttc aaa gtt cag gac ata gac tgagactcat       1082
Ala Thr Tyr Phe Gly Ala Phe Lys Val Gln Asp Ile Asp
            305                 310                 315

ttcgtggaac attagcatgg atgtcctaga tgtttggaaa cttcttaaaa aatggatgat   1142

gtctatacat gtgtaagact actaagagac atggcccacg gtgtatgaaa ctcacagccc   1202
```

```
tctctcttga gcctgtacag gttgtgtata tgtaaagtcc ataggtgatg ttagattcat      1262

ggtgattaca caacggtttt acaattttgt aatgatttcc taagaattga accagattgg      1322

gagaggtatt ccgatgctta tgaaaaactt acacgtgagc tatggaaggg ggtcacagtc      1382

tctgggtcta acccctggac atgtgccact gagaaccttg aaattaagaa gatgccatgt      1442

cattgcaaag aaatgatagt gtgaagggtt aagttctttt gaattgttac attgcgctgg      1502

gacctgcaaa taagttcttt ttttctaatg aggagagaaa aatatatgta tttttatata      1562

atgtctaaag ttatatttca ggtgtaatgt tttctgtgca aagttttgta aattatattt      1622

gtgctatagt atttgattca aaatatttaa aaatgtctca ctgttgacat atttaatgtt      1682

ttaaatgtac agatgtattt aactggtgca ctttgtaatt cccctgaagg tactcgtagc      1742

taaggggca gaatactgtt tctggtgacc acatgtagtt tatttcttta ttcttttaa       1802

cttaatagag tcttcagact tgtcaaaact atgcaagcaa aataaataaa taaaaataaa      1862

atgaatatct tgaataataa gtaggatgtt ggtcaccagg tgcctttcaa atttagaagc      1922

taattgactt taggagctga catagccaaa aaggatacat aataggctac tgaaaatctg      1982

tcaggagtat ttatgcaatt attgaacagg tgtctttttt tacaagagct acaaattgta      2042

aattttgttt cttttttttc ccatagaaaa tgtactatag tttatcagcc aaaaaacaat      2102

ccactttta atttagtgaa agttatttta ttatactgta caataaaagc attgtttctg       2162

aatggcattt tttggtactt aaaaatggc                                        2191


<210>    2
<211>    316
<212>    PRT
<213>    Mus musculus

<400>    2

Met Arg Arg Ala Ser Arg Asp Tyr Gly Lys Tyr Leu Arg Ser Ser Glu
1                 5                   10                  15


Glu Met Gly Ser Gly Pro Gly Val Pro His Glu Gly Pro Leu His Pro
                20                  25                  30


Ala Pro Ser Ala Pro Ala Pro Ala Pro Pro Ala Ala Ser Arg Ser
        35                  40                  45


Met Phe Leu Ala Leu Leu Gly Leu Gly Leu Gly Gln Val Val Cys Ser
    50                  55                  60


Ile Ala Leu Phe Leu Tyr Phe Arg Ala Gln Met Asp Pro Asn Arg Ile
65                  70                  75                  80
```

```
Ser Glu Asp Ser Thr His Cys Phe Tyr Arg Ile Leu Arg Leu His Glu
             85              90                  95

Asn Ala Gly Leu Gln Asp Ser Thr Leu Glu Ser Glu Asp Thr Leu Pro
            100             105                 110

Asp Ser Cys Arg Arg Met Lys Gln Ala Phe Gln Gly Ala Val Gln Lys
            115             120                 125

Glu Leu Gln His Ile Val Gly Pro Gln Arg Phe Ser Gly Ala Pro Ala
            130             135                 140

Met Met Glu Gly Ser Trp Leu Asp Val Ala Gln Arg Gly Lys Pro Glu
145             150                 155                 160

Ala Gln Pro Phe Ala His Leu Thr Ile Asn Ala Ala Ser Ile Pro Ser
            165             170                 175

Gly Ser His Lys Val Thr Leu Ser Ser Trp Tyr His Asp Arg Gly Trp
            180             185                 190

Ala Lys Ile Ser Asn Met Thr Leu Ser Asn Gly Lys Leu Arg Val Asn
            195             200                 205

Gln Asp Gly Phe Tyr Tyr Leu Tyr Ala Asn Ile Cys Phe Arg His His
    210             215                 220

Glu Thr Ser Gly Ser Val Pro Thr Asp Tyr Leu Gln Leu Met Val Tyr
225             230                 235                 240

Val Val Lys Thr Ser Ile Lys Ile Pro Ser Ser His Asn Leu Met Lys
            245             250                 255

Gly Gly Ser Thr Lys Asn Trp Ser Gly Asn Ser Glu Phe His Phe Tyr
            260             265                 270

Ser Ile Asn Val Gly Gly Phe Phe Lys Leu Arg Ala Gly Glu Glu Ile
            275             280                 285

Ser Ile Gln Val Ser Asn Pro Ser Leu Leu Asp Pro Asp Gln Asp Ala
            290             295                 300

Thr Tyr Phe Gly Ala Phe Lys Val Gln Asp Ile Asp
305             310                 315
```